Výsledky vyhledávání - "Michel Fochesato"

Intramuscularly administered herpes zoster subunit vaccine has no effects on fertility, pre- and post-natal development in Sprague-Dawley rats

Autor: Lawrence Segal, Eric Destexhe, Karen Thacker, Nathalie Garçon, Michel Fochesato, Giulia Giordano

Publikováno v: Reproductive Toxicology. 69:297-307

The herpes zoster subunit vaccine (HZ/su) is an investigational vaccine for the prevention of shingles, a disease caused by the varicella zoster virus (VZV). It is composed of recombinant VZV glycoprotein E (gE) and AS01. We assessed the potential to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea468159779da3a8368b547c454d9559
https://doi.org/10.1016/j.reprotox.2017.03.015

Zobrazit plný text záznamu

Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine

Autor: Michel Fochesato, Najoua Dendouga, Mathieu Boxus

Publikováno v: Human Vaccines & Immunotherapeutics

The candidate vaccine HZ/su is being developed to prevent herpes-zoster disease (HZ). HZ occurrence is attributed to declines in varicella-zoster virus (VZV) specific T-cell immunity. HZ/su contains VZV antigen, gE, and Adjuvant System AS01B (liposom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2554b8693d2666e0af50966b5fe93b3c
https://doi.org/10.1080/21645515.2016.1154247

Zobrazit plný text záznamu

Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles

Autor: Sandra L. Giannini, Emmanuel Mertens, Sarah A. Brendle, Agnès Miseur, Michel Fochesato, Neil D. Christensen, Najoua Dendouga, Mathieu Boxus, Karla K. Balogh

Publikováno v: Journal of virology. 90(14)

At least 15 high-risk human papillomaviruses (HPVs) are linked to anogenital preneoplastic lesions and cancer. Currently, there are three licensed prophylactic HPV vaccines based on virus-like particles (VLPs) of the L1 major capsid protein from HPV-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb6e90cc67d757fe5ccc3a54b1e6795b
https://pubmed.ncbi.nlm.nih.gov/27147749

Zobrazit plný text záznamu

Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells

Autor: Catherine Collignon, Najoua Dendouga, Marcelle Van Mechelen, Sandra Morel, Patricia Bourguignon, Kaat Fierens, Bernard Malissen, Bart N. Lambrecht, Sandrine Wouters, Christelle Langlet, Arnaud Didierlaurent, Michel Fochesato, Nathalie Garçon

Publikováno v: Journal of immunology (Baltimore, Md. : 1950). 193(4)

Adjuvant System AS01 is a liposome-based vaccine adjuvant containing 3-O-desacyl-4′-monophosphoryl lipid A and the saponin QS-21. AS01 has been selected for the clinical development of several candidate vaccines including the RTS,S malaria vaccine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9240c6766f3e626524266b312925553
https://pubmed.ncbi.nlm.nih.gov/25024381

Zobrazit plný text záznamu

Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule

Autor: Sandra L. Giannini, Mathieu Boxus, Michel Fochesato, Clarisse Lorin, Florence Thomas, Laurence Lockman

Publikováno v: Vaccine. 32(26)

The HPV-16/18 vaccine (Cervarix®) is a prophylactic vaccine for the prevention of cervical cancer and contains recombinant virus-like particles (VLPs) assembled from the L1 major capsid proteins of human papillomavirus (HPV) strains 16 and 18. Altho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f545ae6f841a63c03e48c649f07c835f
https://pubmed.ncbi.nlm.nih.gov/24731816

Zobrazit plný text záznamu

Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice

Autor: Najoua Dendouga, Sandra L. Giannini, Sally Mossman, Laurence Lockman, Michel Fochesato

Publikováno v: Vaccine. 30(20)

Lack of adequate cell-mediated immunity (CMI) to varicella-zoster virus (VZV) has been associated with higher risks of developing herpes zoster (HZ) and associated post-herpetic neuralgia (PHN), and is of particular concern for older and immunocompro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ed3b62e440b01bead2941809455d7f9
https://pubmed.ncbi.nlm.nih.gov/22326899

Zobrazit plný text záznamu